公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
1992 | Lobar bronchioloalveolar carcinoma: an ultrasound study. | JEN-CHUNG KO ; PAN-CHYR YANG ; KWEN-TAY LUH ; Kuo S.H.; Chang D.B.; CHONG-JEN YU | Journal of the Formosan Medical Association = Taiwan yi zhi | 3 | 0 | |
2013 | Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cells | JEN-CHANG KO ; Huang Y.-C.; Chen H.-J.; Tseng S.-C.; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Weng S.-H.; Chiou R.Y.Y.; Lin Y.-W. | Basic and Clinical Pharmacology and Toxicology | 17 | 16 | |
2015 | Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells | JEN-CHANG KO ; Wang T.-J.; Chang P.-Y.; Syu J.-J.; Chen J.-C.; Chen C.-Y.; Jian Y.-T.; Jian Y.-J.; Zheng H.-Y.; Chen W.-C.; Lin Y.-W. | Biochemical Pharmacology | 7 | 5 | |
2011 | Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine | JEN-CHUNG KO ; Tsai M.-S.; Kuo Y.-H.; Chiu Y.-F.; Weng S.-H.; Su Y.-C.; Lin Y.-W. | Biochemical Pharmacology | 29 | 25 | |
2020 | Nitroglycerin Enhances Cisplatin-Induced Cytotoxicity via AKT Inactivation and Thymidylate Synthase Downregulation in Human Lung Cancer Cells | JEN-CHANG KO ; Chen J.-C.; Yen T.-C.; Chen T.-Y.; Ma P.-F.; Lin Y.-C.; Cheng H.-H.; Taso Y.-C.; Lin Y.-W. | Pharmacology | 3 | 5 | |
2022 | Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells | JEN-CHUNG KO | Nitroglycerin-induced downregulation of AKT- and ERK1/2-mediated radiation-sensitive 52 expression to enhance pemetrexed-induced cytotoxicity in human lung cancer cells | 2 | 2 | |
2020 | Nontuberculous mycobacterial lung disease epidemiology in Taiwan: A systematic review | MENG-RUI LEE ; LIH-YU CHANG ; JEN-CHANG KO ; HAO-CHIEN WANG ; Huang Y.-W. | Journal of the Formosan Medical Association | 12 | 8 | |
2023 | Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early-stage non-small cell lung cancer patients | SHENG-KAI LIANG ; Wu, Chang-Wei; Chang, Ching-I; LI-TA KENG ; MENG-RUI LEE ; JANN-YUAN WANG ; JEN-CHUNG KO ; WEI-YU LIAO ; KUAN-YU CHEN ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU | Cancer medicine | 0 | 0 | |
2019 | Outcome of stage IV cancer patients receiving in-hospital cardiopulmonary resuscitation: a population-based cohort study | MENG-RUI LEE ; KAI-LUN YU ; HUNG-YANG KUO ; TSUNG-HAO LIU ; JEN-CHUNG KO ; JAW-SHIUN TSAI ; JANN-YUAN WANG | Scientific Reports | 16 | 13 | |
1994 | Panhypopituitarism caused by solitary parasellar metastasis from lung cancer | JEN-CHANG KO ; PAN-CHYR YANG ; TIEN-SHANG HUANG ; KUN-HUEI YEH ; Kuo S.-H.; KWEN-TAY LUH | Chest | 19 | 17 | |
2013 | Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells | Chen R.-S.; JEN-CHANG KO ; Chiu H.-C.; Wo T.-Y.; Huang Y.-J.; Tseng S.-C.; Chen H.-J.; Huang Y.-C.; Jian Y.-J.; Lee W.-T.; Lin Y.-W. | Naunyn-Schmiedeberg's Archives of Pharmacology | 10 | 9 | |
2018 | Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study | SHENG-KAI LIANG ; MENG-RUI LEE ; WEI-YU LIAO ; CHAO-CHI HO ; JEN-CHUNG KO ; JIN-YUAN SHIH | Oncotarget | 17 | 0 | |
2018 | Psychological distress and coping strategies among women with incurable lung cancer: a qualitative study | Liao Y.-C.; WEI-YU LIAO ; Sun J.-L.; JEN-CHANG KO ; CHONG-JEN YU | Supportive Care in Cancer | 22 | 18 | |
2017 | Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma | SHENG-KAI LIANG ; MIN-SHU HSIEH ; MENG-RUI LEE ; LI-TA KENG ; JEN-CHUNG KO ; JIN-YUAN SHIH | Oncotarget | 55 | 52 | |
2015 | Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells | JEN-CHANG KO ; Syu J.-J.; Chen J.-C.; Wang T.-J.; Chang P.-Y.; Chen C.-Y.; Jian Y.-T.; Jian Y.-J.; Lin Y.-W. | Basic and Clinical Pharmacology and Toxicology | 22 | 15 | |
2009 | The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells | JEN-CHUNG KO ; Wang L.-H.; Jhan J.-Y.; Ciou S.-C.; Hong J.-H.; Lin S.-T.; Lin Y.-W. | Lung Cancer | 9 | 9 | |
2008 | Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells | JEN-CHUNG KO ; Hong J.-H.; Wang L.-H.; Cheng C.-M.; Ciou S.-C.; Lin S.-T.; Jheng M.-Y.; Lin Y.-W. | Molecular Cancer Therapeutics | 38 | 35 | |
2008 | The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer | JEN-CHUNG KO ; Hong J.-H.; Wang L.-H.; Lin Y.-W. | Experimental Cell Research | 14 | 14 | |
2009 | Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells | JEN-CHUNG KO ; Ciou S.-C.; Jhan J.-Y.; Cheng C.-M.; Su Y.-J.; Chuang S.-M.; Lin S.-T.; Chang C.-C.; Lin Y.-W. | Molecular Cancer Research | 45 | 40 | |
2016 | Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression | JEN-CHUNG KO ; Zheng H.-Y.; Chen W.-C.; Peng Y.-S.; Wu C.-H.; Wei C.-L.; Chen J.-C.; Lin Y.-W. | Biochemical Pharmacology | 10 | 10 |